Gastrointestinal vasculitis due to systemic lupus erythematosus treated with rituximab: a case report

dc.contributor.authorKenar, Gokce
dc.contributor.authorAtay, Kadri
dc.contributor.authorYuksek, Gul E.
dc.contributor.authorOz, Burak
dc.contributor.authorKoca, Suleyman Serdar
dc.date.accessioned2026-08-12T17:18:25Z
dc.date.issued2020
dc.departmentFırat Üniversitesi
dc.description.abstractBackground Patients with systemic lupus erythematosus may present with variable gastrointestinal manifestations including peritonitis, pancreatitis, enteritis, and vasculitis. Gastrointestinal vasculitis is one of the most devastating complications of systemic lupus erythematosus, with a mortality rate of 50% when it progresses to bowel ischemia and is complicated by hemorrhage or perforation. Case report A young female patient known to have systemic lupus erythematosus, lupus nephritis, and antiphospholipid antibody syndrome, on immunosuppressive treatment presented to the emergency department with acute abdominal pain and nausea. The clinical findings were first associated with an acute flare of lupus nephritis according to the assessments with active laboratory parameters. However, over a short time the abdominal pain worsened and was accompanied by peritonitis and gastrointestinal hemorrhage. The computed tomography scans demonstrated a dilated bowel and thickening of the bowel compatible with gastrointestinal vasculitis. The upper and lower gastrointestinal endoscopy supported the diagnosis of vasculitis by showing multiple ulcerative lesions along the gastrointestinal tract. The patient was successfully treated with pulse corticosteroids urgently, with a fast response to subsequent rituximab therapy without any relapses. Treatment with cyclophosphamide was not preferred because the patient had a high cumulative dose. Conclusion Gastrointestinal vasculitis should be a primary differential diagnosis in patients with systemic lupus erythematosus presenting with abdominal pain because of its rapid progression and high mortality. The treatment choice has been suggested as cyclophosphamide for severe cases in the literature. In this case report, a patient successfully treated with rituximab without any relapses was documented.
dc.identifier.doi10.1177/0961203320910803
dc.identifier.endpage643
dc.identifier.issn0961-2033
dc.identifier.issn1477-0962
dc.identifier.issue6
dc.identifier.orcid0000-0001-9762-2401
dc.identifier.orcid0000-0003-4995-430X
dc.identifier.pmid32188302
dc.identifier.scopus2-s2.0-85082195398
dc.identifier.scopusqualityQ2
dc.identifier.startpage640
dc.identifier.urihttps://doi.org/10.1177/0961203320910803
dc.identifier.urihttps://hdl.handle.net/11508/53038
dc.identifier.volume29
dc.identifier.wosWOS:000523887400001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSage Publications Ltd
dc.relation.ispartofLupus
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjectSystemic lupus erythematous
dc.subjectgastrointestinal vasculitis
dc.subjectlupus enteritis
dc.subjectrituximab
dc.titleGastrointestinal vasculitis due to systemic lupus erythematosus treated with rituximab: a case report
dc.typeArticle

Dosyalar